Ticker Search:  Getting Started | Register | Videos | Newsletter | Partners | Login    

Basics
Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals Inc is a biotechnology company. It is engaged in the research and development of small molecule drugs for infectious diseases. The Group uses its chemistry-driven approach & drug discovery capabilities to develop its products.
IPO Date: March 21, 2013
Sector: Healthcare
Industry: Biotech
Market Cap: $108.8M
Activated in VL: True
Average Daily Range
Avg Daily Range: $0.93 | 2.20%
Avg Daily Range (30 D): $0.17 | 3.15%
Avg Daily Range (90 D): $0.21 | 3.40%
Institutional Daily Volume
Avg Daily Volume: .19M
Avg Daily Volume (30 D): .21M
Avg Daily Volume (90 D): .38M
Trade Size
Avg Trade Size (Sh.): 73
Avg Trade Size (Sh.) (30 D): 75
Avg Trade Size (Sh.) (90 D): 93
Institutional Trades
Total Inst.Trades: 2,594
Avg Inst. Trade: $1.8M
Avg Inst. Trade (30 D): $.69M
Avg Inst. Trade (90 D): $1.63M
Avg Inst. Trade Volume: .04M
Avg Inst. Trades (Per Day): 1
Market Closing Trades
Avg Closing Trade: $1.92M
Avg Closing Trade (30 D): $.69M
Avg Closing Trade (90 D): $.92M
Avg Closing Volume: 38.4K
       
News
Nov 4, 2024 @ 6:00 PM
Urticaria Clinical Trial Pipeline Accelerates: 20+...
Source: Delveinsight
May 6, 2024 @ 9:10 PM
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Top...
Source: Zacks Equity Research
Feb 7, 2024 @ 10:10 PM
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Lag...
Source: Zacks Equity Research
Jan 5, 2024 @ 8:09 AM
Strength Seen in Enanta Pharmaceuticals (ENTA): Ca...
Source: Zacks Equity Research
Dec 20, 2023 @ 11:00 AM
The Zacks Analyst Blog Highlights Enanta, OneConne...
Source: Zacks Equity Research
Financials
  TTM Q1 2025 Q3 2024
Basic EPS $-1.05 $-1.07
Diluted EPS $-1.05 $-1.07
Revenue $ $ 16.96M $ 17.97M
Gross Profit $ $ $
Net Income / Loss $ -104.93M $ -22.29M $ -22.66M
Operating Income / Loss $ $ -23.54M $ -24.19M
Cost of Revenue $ $ $
Net Cash Flow $ $ 47.12M $ -27.77M
PE Ratio